Alerts will be sent to your verified email
Verify EmailTTKHLTCARE
TTK Healthcare
|
3B Blackbio Dx
|
Nureca Ltd.
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
22.38 % | n/a | n/a |
R&D as a % of Total Sales
|
0.15 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
21.34 % | 31.8 % | 9.17 % |
5yr average Equity Multiplier
|
1.49 | 1.27 | 1.11 |
5yr Average Asset Turnover Ratio
|
0.97 | 0.56 | 0.73 |
5yr Avg Net Profit Margin
|
23.04 % | 40.4 % | 6.15 % |
Price to Book
|
1.7 | 4.71 | 1.37 |
P/E
|
22.12 | 26.53 | 315.73 |
5yr Avg Cash Conversion Cycle
|
-31.94 Days | 152.2 Days | 81.78 Days |
Inventory Days
|
43.46 Days | 35.71 Days | 97.74 Days |
Days Receivable
|
41.18 Days | 172.8 Days | 7.39 Days |
Days Payable
|
113.69 Days | 58.4 Days | 26.16 Days |
5yr Average Interest Coverage Ratio
|
14.83 | 328.3 | 19.65 |
5yr Avg ROCE
|
7.45 % | 38.24 % | 12.65 % |
5yr Avg Operating Profit Margin
|
4.27 % | 47.2 % | 3.76 % |
5 yr average Debt to Equity
|
0.06 | 0.03 | 0.0 |
5yr CAGR Net Profit
|
38.52 % | 33.12 % | -55.06 % |
5yr Average Return on Assets
|
16.02 % | 23.56 % | 7.53 % |
Shareholdings
|
|||
Promoter Holding
|
74.56 % | 41.28 % | 64.3 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 2.85 % | -5.7 % |
Change in Mutual Fund Holding (3 Yrs)
|
-2.39 % | 0.0 | -1.35 % |
TTK Healthcare
|
3B Blackbio Dx
|
Nureca Ltd.
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|